Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis

Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis

Andreas Karabis,1 Leandro Lindner,2 Michelle Mocarski,3 Eline Huisman,1 Andrew Greening4 1MAPI Consultancy, AX Houten, The Netherlands; 2Almirall SA, Barcelona, Spain; 3Health Economics and Outcomes Research, Forest Research Institute, Jersey City, NJ, USA; 4University of Edinburgh, Lothian Universi...

Full description

Bibliographic Details
Main Authors:	Karabis A, Lindner L, Mocarski M, Huisman E, Greening A
Format:	Article
Language:	English
Published:	Dove Medical Press 2013-09-01
Series:	International Journal of COPD
Online Access:	http://www.dovepress.com/comparative-efficacy-of-aclidinium-versus-glycopyrronium-and-tiotropiu-a14290

Similar Items

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years
by: Karabis A, et al.
Published: (2014-04-01)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
by: Antonio Molino, et al.
Published: (2017-09-01)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
by: Anzueto AR, et al.
Published: (2017-05-01)

Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK
by: Eklund O, et al.
Published: (2016-06-01)

Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)
by: Marin JM, et al.
Published: (2016-06-01)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
by: Sethi S, et al.
Published: (2019-03-01)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
by: Buhl R, et al.
Published: (2012-10-01)

Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study
by: Monteagudo M, et al.
Published: (2017-04-01)

Cost versus utility of aclidinium bromide 400 μg plus formoterol fumarate dihydrate 12 μg compared to aclidinium bromide 400 μg alone in the management of moderate-to-severe COPD
by: Ramos M, et al.
Published: (2016-09-01)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
by: Buhl R, et al.
Published: (2014-03-01)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
by: Contoli M, et al.
Published: (2016-12-01)

Tiotropium as essential maintenance therapy in COPD
by: M. Decramer
Published: (2006-12-01)

Clinical use of aclidinium in patients with COPD
by: Reid DJ, et al.
Published: (2014-04-01)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
by: Beier J, et al.
Published: (2017-06-01)

COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study
by: Ichinose M, et al.
Published: (2018-07-01)

Real-life effectiveness of indacaterol–glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study
by: Kaplan A, et al.
Published: (2019-01-01)

Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium tiotropium: the RED trial
by: Jessie Beaulieu, et al.
Published: (2020-07-01)

Tiotropium/olodaterol versus tiotropium in Japanese patients with COPD: results from the DYNAGITO study [Corrigendum]
by: Ichinose M, et al.
Published: (2018-10-01)

An update on the efficacy and safety of aclidinium bromide in patients with COPD
by: Khuder Alagha, et al.
Published: (2011-02-01)

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
by: Tara Rheault, et al.
Published: (2016-04-01)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
by: Sang Haak Lee, et al.
Published: (2021-04-01)

Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium
by: Lopez-Campos JL, et al.
Published: (2015-01-01)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
by: Incorvaia C, et al.
Published: (2016-02-01)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
by: Mantero M, et al.
Published: (2018-07-01)

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
by: Chan M, et al.
Published: (2018-04-01)

A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study
by: Lehmann S, et al.
Published: (2019-01-01)

Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study
by: Danilo Cortozi Berton, et al.

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
by: Dhvani Shah, et al.
Published: (2018-05-01)

Vliv Glycopyrronium Bromide a Tiotropium Bromide na proteiny těsných spojů v hematoencefalické bariéře in vitro
by: Vaněček, Václav
Published: (2007)

Efficacy of tiotropium in the prevention of exacerbations of COPD
by: Antonio Anzueto, et al.
Published: (2009-06-01)

Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis
by: Ismaila AS, et al.
Published: (2015-11-01)

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
by: Moitra S, et al.
Published: (2015-04-01)

Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis
by: Huisman EL, et al.
Published: (2015-09-01)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
by: Watz H, et al.
Published: (2017-08-01)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
by: D&rsquo;Urzo A
Published: (2013-08-01)

Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis
by: Marc Miravitlles, et al.
Published: (2017-11-01)

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD
by: Andreas S, et al.
Published: (2020-08-01)

Cannot write session to /tmp/vufind_sessions/sess_tbtsqa36pa56phi40papm323ve